Growth Hormone Treatment of Children with Prader-Willi Syndrome as Reported to KIGS: First-Year Growth Hormone E Martin Ritzén KIGS 10 Year Book, 1999

E M Ritzén - KIGS 10 Year Book, 1999 Auxological characteristics at start of GH treatment of all patients with Prader-Willi syndrome enrolled in KIGS WHI, weight-for-height index; BMI, body mass index; SDS, standard deviation score

E M Ritzén - KIGS 10 Year Book, 1999 Distribution of height SDS versus age for male patients with PWS in the KIGS database at the start of GH treatment (1/2) There is a significant loss of height SDS with advancing age that seems to increase in adolescence,, medican;, + 2 SD;, -4 SD (syndrome-specific standards; Wollmann et al 1997). Shaded area, normative standards (Tanner et al 1966)

E M Ritzén - KIGS 10 Year Book, 1999 Distribution of height SDS versus age for female patients with PWS in the KIGS database at the start of GH treatment (2/2) There is a significant loss of height SDS with advancing age that seems to increase in adolescence,, medican;, + 2 SD;, -4 SD (syndrome-specific standards; Wollmann et al 1997). Shaded area, normative standards (Tanner et al 1966)

E M Ritzén - KIGS 10 Year Book, 1999 Body mass index (BMI) SDS versus chronological age of all children with PWS at the start of GH treatment BMI (SDS)

E M Ritzén - KIGS 10 Year Book, 1999 KIGS data summarising baseline characteristics and first-year response to GH treatment of children with PWS SDS, standard deviation score; BMI, body mass index. a GH dose, 0.7 U/kg/week (n=15), b GH dose, 1.4 U/kg/week (n=12) c Weight-for-height index, 99.9% (10th-90th percentiles, %)